✦ LIBER ✦
62 Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer
✍ Scribed by S. Geeganage; L. Sams; S. Joseph; T. Shepherd; R. Dally; L. Brail; T. Wang; A. Capen; G. Rodgers; E. Perkins
- Book ID
- 119602745
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 44 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.